Macrogenics (MGNX) EBT Margin (2012 - 2026)
Macrogenics (MGNX) posted quarterly EBT Margin of 187.28% for Q1 2026, up 13651.0% year-over-year from N/an in Q1 2025, and down 417.08% quarter-over-quarter from 36.22% in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) EBT Margin (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported EBT Margin for 15 consecutive years, with 187.28% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 13651.0% year-over-year to 187.28%; the TTM figure through Mar 2026 stood at 46.58% (down 1421.0% YoY), while the FY2025 annual figure was 50.36%, down 634.0% from the prior year.
- EBT Margin declined to 187.28% in Q1 2026 per MGNX's latest filing, from 36.22% in the prior quarter.
- Across five years, EBT Margin topped out at 50.86% in Q3 2024 and bottomed at 1100.56% in Q1 2024.
- Historically, EBT Margin has averaged 261.74% across 5 years, with a median of 187.28% in 2026.
- Annual changes were most pronounced in 2022 — EBT Margin soared 274367 bps — and 2024, when it slumped 91174 bps.
- Macrogenics' EBT Margin stood at 16.39% in 2022, then slumped by 2908 bps to 460.39% in 2023, then surged by 92 bps to 36.19% in 2024, then declined by 0 bps to 36.22% in 2025, then plunged by 417 bps to 187.28% in 2026.
- Business Quant data shows MGNX's EBT Margin at 187.28% in Q1 2026, 36.22% in Q4 2025, and 23.09% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -212.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -212.12% |
| Mar 31, 2026 | -184.49% |
| Dec 31, 2025 | -36.22% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | -620.35% |
| Mar 31, 2025 | -323.79% |
| Dec 31, 2024 | -36.19% |
| Sep 30, 2024 | 50.86% |
| Jun 30, 2024 | -515.55% |
| Mar 31, 2024 | -602.84% |
| Dec 31, 2023 | -460.39% |
| Sep 30, 2023 | -341.46% |
| Jun 30, 2023 | -348.17% |
| Mar 31, 2023 | -159.54% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | -59.80% |
| Jun 30, 2022 | -160.76% |
| Mar 31, 2022 | -600.29% |
| Dec 31, 2021 | -411.65% |
| Sep 30, 2021 | -338.32% |